ISSCR News
Expanding Opportunities for Students
For the second year now, we have created opportunities for early career scientists, primarily trainees and postdoctoral scholars, to design their dream session at the ISSCR Annual Meeting. Not only does this give early career researchers experience with developing scientific programming, but also encourages them to build new relationships with scientists from different institutions who can share their work as part of the theme of the session. The Science Spotlight Sessions will be held on Wednesday 10 July from 4:00 to 5:30 PM at ISSCR 2024.
Member Spotlight: Elaine Fuchs, PhD
ISSCR is a wonderful international community of colleagues. Science has no borders and scientists are in many ways able to cut across political boundaries, and admire and learn from each other no matter where we live and work.
The ISSCR Provides Comments on FDA’s Draft Guidance for Potency Assurance for Cellular and Gene Therapy Products
On 5 March 2023, the ISSCR submitted comments on the Food and Drug Administration’s draft guidance for Potency Assurance for Cellular and Gene Therapy (CGT) Products. ISSCR appreciates FDA’s commitment to assuring the potency of human CGT products at all stages of the product lifecycle. This guidance from the FDA will help our members, who are at the forefront of research and innovation, in their work.
Bayer and BlueRock Therapeutics Join the City of Hamburg and Life Sciences Nord to Co-Sponsor ISSCR 2024 in Hamburg, Germany
Find your inspiration at ISSCR 2024, The Global Stem Cell Event, taking place 10-13 July 2024 in Hamburg, Germany. The international stem cell community’s most anticipated event of the year showcases impactful research and clinical applications in a field that is driving clinical advances with the potential to bring new approaches to alleviating intractable diseases and disorders.
Highlight from Stem Cell Reports: New Type of Stem Cells Contains Potential for Knee Cartilage Regeneration in Arthritic Mice
Osteoarthritis (OA) is a debilitating joint disease which affects over 500 million people worldwide, with trends increasing as populations age. OA is caused by progressive, irreversible degeneration of joint cartilage, leading to pain, swelling and immobility in the affected joint. Current therapies focus on symptom relief but cannot restore degenerated cartilage.
A potentially alternative treatment is the regeneration of cartilage from stem cells. Importantly, not all types of stem cells can make cartilage and earlier clinical trials with mesenchymal stem or stromal cells (MSCs) obtained did not convincingly show that MSCs make new cartilage when given to OA patients.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .